IBDEI0S6 ; ; 12-MAY-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 12, 2016
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,28324,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,28324,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,28325,0)
 ;;=C91.02^^105^1378^2
 ;;^UTILITY(U,$J,358.3,28325,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28325,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,28325,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,28325,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,28326,0)
 ;;=C91.10^^105^1378^13
 ;;^UTILITY(U,$J,358.3,28326,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28326,1,3,0)
 ;;=3^Chronic lymphocytic leuk of B-cell type not achieve remis
 ;;^UTILITY(U,$J,358.3,28326,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,28326,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,28327,0)
 ;;=C91.11^^105^1378^14
 ;;^UTILITY(U,$J,358.3,28327,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28327,1,3,0)
 ;;=3^Chronic lymphocytic leukemia of B-cell type in remission
 ;;^UTILITY(U,$J,358.3,28327,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,28327,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,28328,0)
 ;;=C91.12^^105^1378^15
 ;;^UTILITY(U,$J,358.3,28328,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28328,1,3,0)
 ;;=3^Chronic lymphocytic leukemia of B-cell type in relapse
 ;;^UTILITY(U,$J,358.3,28328,1,4,0)
 ;;=4^C91.12
 ;;^UTILITY(U,$J,358.3,28328,2)
 ;;=^5001767
 ;;^UTILITY(U,$J,358.3,28329,0)
 ;;=D47.1^^105^1378^16
 ;;^UTILITY(U,$J,358.3,28329,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28329,1,3,0)
 ;;=3^Chronic myeloproliferative disease
 ;;^UTILITY(U,$J,358.3,28329,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,28329,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,28330,0)
 ;;=C94.42^^105^1378^5
 ;;^UTILITY(U,$J,358.3,28330,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28330,1,3,0)
 ;;=3^Acute panmyelosis with myelofibrosis, in relapse
 ;;^UTILITY(U,$J,358.3,28330,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,28330,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,28331,0)
 ;;=C94.41^^105^1378^6
 ;;^UTILITY(U,$J,358.3,28331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28331,1,3,0)
 ;;=3^Acute panmyelosis with myelofibrosis, in remission
 ;;^UTILITY(U,$J,358.3,28331,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,28331,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,28332,0)
 ;;=C94.40^^105^1378^4
 ;;^UTILITY(U,$J,358.3,28332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28332,1,3,0)
 ;;=3^Acute panmyelosis w myelofibrosis not achieve remission
 ;;^UTILITY(U,$J,358.3,28332,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,28332,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,28333,0)
 ;;=D47.2^^105^1378^55
 ;;^UTILITY(U,$J,358.3,28333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28333,1,3,0)
 ;;=3^Monoclonal gammopathy
 ;;^UTILITY(U,$J,358.3,28333,1,4,0)
 ;;=4^D47.2
 ;;^UTILITY(U,$J,358.3,28333,2)
 ;;=^5002257
 ;;^UTILITY(U,$J,358.3,28334,0)
 ;;=C88.0^^105^1378^76
 ;;^UTILITY(U,$J,358.3,28334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28334,1,3,0)
 ;;=3^Waldenstrom macroglobulinemia
 ;;^UTILITY(U,$J,358.3,28334,1,4,0)
 ;;=4^C88.0
 ;;^UTILITY(U,$J,358.3,28334,2)
 ;;=^5001748
 ;;^UTILITY(U,$J,358.3,28335,0)
 ;;=C81.70^^105^1378^41
 ;;^UTILITY(U,$J,358.3,28335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28335,1,3,0)
 ;;=3^Hodgkin Lymphoma,Classical,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,28335,1,4,0)
 ;;=4^C81.70
 ;;^UTILITY(U,$J,358.3,28335,2)
 ;;=^5001441
 ;;^UTILITY(U,$J,358.3,28336,0)
 ;;=C81.79^^105^1378^40
 ;;^UTILITY(U,$J,358.3,28336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28336,1,3,0)
 ;;=3^Hodgkin Lymphoma,Classical,Extrnod/Solid Organ Sites NEC
 ;;^UTILITY(U,$J,358.3,28336,1,4,0)
 ;;=4^C81.79
 ;;^UTILITY(U,$J,358.3,28336,2)
 ;;=^5001450
 ;;^UTILITY(U,$J,358.3,28337,0)
 ;;=C82.50^^105^1378^20
 ;;^UTILITY(U,$J,358.3,28337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28337,1,3,0)
 ;;=3^Diffuse Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,28337,1,4,0)
 ;;=4^C82.50
 ;;^UTILITY(U,$J,358.3,28337,2)
 ;;=^5001511
 ;;^UTILITY(U,$J,358.3,28338,0)
 ;;=C82.59^^105^1378^19
 ;;^UTILITY(U,$J,358.3,28338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28338,1,3,0)
 ;;=3^Diffuse Follicle Center Lymphoma,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,28338,1,4,0)
 ;;=4^C82.59
 ;;^UTILITY(U,$J,358.3,28338,2)
 ;;=^5001520
 ;;^UTILITY(U,$J,358.3,28339,0)
 ;;=C82.80^^105^1378^24
 ;;^UTILITY(U,$J,358.3,28339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28339,1,3,0)
 ;;=3^Follicular Lymphoma,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,28339,1,4,0)
 ;;=4^C82.80
 ;;^UTILITY(U,$J,358.3,28339,2)
 ;;=^5001531
 ;;^UTILITY(U,$J,358.3,28340,0)
 ;;=C82.89^^105^1378^23
 ;;^UTILITY(U,$J,358.3,28340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28340,1,3,0)
 ;;=3^Follicular Lymphoma,Extrnod/Solid Organ Sites NEC
 ;;^UTILITY(U,$J,358.3,28340,1,4,0)
 ;;=4^C82.89
 ;;^UTILITY(U,$J,358.3,28340,2)
 ;;=^5001540
 ;;^UTILITY(U,$J,358.3,28341,0)
 ;;=C83.00^^105^1378^75
 ;;^UTILITY(U,$J,358.3,28341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28341,1,3,0)
 ;;=3^Small Cell B-Cell Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,28341,1,4,0)
 ;;=4^C83.00
 ;;^UTILITY(U,$J,358.3,28341,2)
 ;;=^5001551
 ;;^UTILITY(U,$J,358.3,28342,0)
 ;;=C83.09^^105^1378^74
 ;;^UTILITY(U,$J,358.3,28342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28342,1,3,0)
 ;;=3^Small Cell B-Cell Lymphoma,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,28342,1,4,0)
 ;;=4^C83.09
 ;;^UTILITY(U,$J,358.3,28342,2)
 ;;=^5001560
 ;;^UTILITY(U,$J,358.3,28343,0)
 ;;=C83.30^^105^1378^21
 ;;^UTILITY(U,$J,358.3,28343,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28343,1,3,0)
 ;;=3^Diffuse Large B-Cell Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,28343,1,4,0)
 ;;=4^C83.30
 ;;^UTILITY(U,$J,358.3,28343,2)
 ;;=^5001571
 ;;^UTILITY(U,$J,358.3,28344,0)
 ;;=C83.80^^105^1378^66
 ;;^UTILITY(U,$J,358.3,28344,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28344,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,28344,1,4,0)
 ;;=4^C83.80
 ;;^UTILITY(U,$J,358.3,28344,2)
 ;;=^5001601
 ;;^UTILITY(U,$J,358.3,28345,0)
 ;;=C83.89^^105^1378^65
 ;;^UTILITY(U,$J,358.3,28345,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28345,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,28345,1,4,0)
 ;;=4^C83.89
 ;;^UTILITY(U,$J,358.3,28345,2)
 ;;=^5001610
 ;;^UTILITY(U,$J,358.3,28346,0)
 ;;=C83.90^^105^1378^68
 ;;^UTILITY(U,$J,358.3,28346,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28346,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,28346,1,4,0)
 ;;=4^C83.90
 ;;^UTILITY(U,$J,358.3,28346,2)
 ;;=^5001611
 ;;^UTILITY(U,$J,358.3,28347,0)
 ;;=C83.99^^105^1378^67
 ;;^UTILITY(U,$J,358.3,28347,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28347,1,3,0)
 ;;=3^Non-Follicular Lymphoma,Unspec,Extranod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,28347,1,4,0)
 ;;=4^C83.99
 ;;^UTILITY(U,$J,358.3,28347,2)
 ;;=^5001620
 ;;^UTILITY(U,$J,358.3,28348,0)
 ;;=C84.10^^105^1378^73
 ;;^UTILITY(U,$J,358.3,28348,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28348,1,3,0)
 ;;=3^Sezary Disease,Unspec Site
 ;;^UTILITY(U,$J,358.3,28348,1,4,0)
 ;;=4^C84.10
 ;;^UTILITY(U,$J,358.3,28348,2)
 ;;=^5001631
 ;;^UTILITY(U,$J,358.3,28349,0)
 ;;=C84.19^^105^1378^72
 ;;^UTILITY(U,$J,358.3,28349,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28349,1,3,0)
 ;;=3^Sezary Disease,Extrnod/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,28349,1,4,0)
 ;;=4^C84.19
 ;;^UTILITY(U,$J,358.3,28349,2)
 ;;=^5001640
 ;;^UTILITY(U,$J,358.3,28350,0)
 ;;=C84.40^^105^1378^70
 ;;^UTILITY(U,$J,358.3,28350,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,28350,1,3,0)
 ;;=3^Peripheral T-Cell Lymphoma,Unspec Site NEC
 ;;^UTILITY(U,$J,358.3,28350,1,4,0)
 ;;=4^C84.40
 ;;^UTILITY(U,$J,358.3,28350,2)
 ;;=^5001641
 ;;^UTILITY(U,$J,358.3,28351,0)
 ;;=C84.49^^105^1378^69
 ;;^UTILITY(U,$J,358.3,28351,1,0)
 ;;=^358.31IA^4^2
